Topic:

R&D

Latest Headlines

Latest Headlines

Clearside's novel eye drug delivery tech shows promise in latest clinical trial

Eyecare company Clearside Biomedical announced that patients treated with its injectable eye disease candidate demonstrated improved vision, as it tries to become the first to commercialize suprachoroidal delivery.

Biogen Alzheimer's drug reignites excitement

The success of Biogen Idec's closely watched antibody targeting beta amyloid proteins in Alzheimer's disease is again bringing some excitement to a category that has defeated earlier enthusiasm as drugs have failed in trials.

Sebacia reveals positive data for acne-fighting gold microparticle device

Dermatology outfit Sebacia is touting promising results for its acne-treating technology from two recent clinical studies that show its gold microparticles significantly reduced acne in patients.  

GE tech hub develops innovative handheld probe for bedsore monitoring

As the med tech industry turns its attention to devices that can treat and prevent bedsores, a team of GE researchers is developing an innovative handheld probe that can prevent the sores, or pressure ulcers, from forming during hospital stays.

Researchers examine role of dog ownership on beneficial bacteria

The University of Arizona has launched a study designed to explore whether dogs promote the growth of probiotics--the so-called good bacteria--in their owners.

Sanofi finally unloads an embattled R&D site in $270M Evotec deal

Sanofi is shipping more than 200 researchers to German outsourcing firm Evotec as it finally gets out of a French R&D site whose fate led to a squabble with the local government, reaching a compromise the company believes will leave all sides appeased.

Cloud Pharmaceuticals allies with U. of Florida to advance in silico pipeline

Cloud Pharmaceuticals has taken the next step in its push to create a pipeline of drugs discovered using a computer-based design process, hooking up with the University of Florida to transition its computer-discovered drugs into traditional preclinical research.

Maker of microspheres for local delivery of radiation suffers clinical trial setback

Sirtex Medical's clinical trial of its microspheres for targeted delivery of radioactive particles did not live up to expectations. Investors dumped the Australian company's stock in a hurry beginning March 13. It began the following week at $15, or a stunning 60% lower than before the bad news was delivered.

What, Juno Therapeutics worried about its cash burn? Not likely

Juno Therapeutics quickly built a reputation as one of the hottest biotechs in the world, raising hundreds of millions of dollars inside a year and capping it with a go-go IPO for its cancer drug pipeline that helped inspire a surge for the sector. And now that the newly public biotech has filed its first 10-K, Juno can feel the backlash as it outlines just how fast it can spend that huge cache of cash, missing a consensus estimate on projected losses by a market mile.

Google's mystery biotech Calico partners with the Broad on aging-related drugs

Slowly but surely, Google's star-driven biotech Calico is laying the foundation for what promises to be a major biotech focused on some of the biggest diseases that limit longevity. There's a Big Pharma partnership with AbbVie, a development deal down in Texas and now it's time to team up with top scientists. Earlier in the week Harvard and MIT's renowned Broad Institute signed on to work with Calico on pushing new therapies into the clinic.